Profile data is unavailable for this security.
About the company
Basilea Pharmaceutica AG Allschwil, formerly known as Basilea Pharmaceutica AG, is a Switzerland-based commercial-stage biopharmaceutical company. The Company operates in one segment, which is the discovery, development, and commercialization of pharmaceutical products to meet the needs of patients with severe bacterial and fungal infections. It launched two hospital brands, Cresemba, which is an intravenous and oral drug for the treatment of invasive fungal infections, and Zevtera, which is an intravenous antibiotic for the treatment of severe bacterial infections, especially pneumonia. Additionally, the Company has several preclinical anti-infective assets in their portfolio. Company's products are present in United States, Canada, Europe, Asia, and Africa.
- Revenue in CHF (TTM)149.02m
- Net income in CHF-652.00k
- Incorporated2002
- Employees156.00
- LocationBasilea Pharmaceutica AG AllschwilHegenheimermattweg 167bALLSCHWIL 4123SwitzerlandCHE
- Phone+41 616061111
- Fax+41 616061112
- Websitehttps://www.basilea.com/
More ▼
Mergers & acquisitions
| Acquired company | BSLN:SWX since announced | Transaction value |
|---|---|---|
| Spexis AG-Preclinical Antibiotics Program | 16.17% | 2.35m |
Data delayed at least 15 minutes, as of Nov 22 2024 16:30 GMT.
Peer analysis
Key Information
- Key Information
- Stock Performance
- Per Share Data
- Efficiency
- Management Effectiveness
- Profitability
- Financial Strength
- Growth Rates
| Company | Revenue (TTM) | Net income (TTM) | Market cap | Employees | Price/earnings (TTM) | Price/book value (MRQ) | Price/cash flow (TTM) | Price/sales (TTM) | EPS (excl. extraordinary items, TTM) | EPS (incl. extraordinary items, TTM) | Revenue per share (TTM) | Book value per share (MRQ) | Asset turnover (TTM) | Inventory turnover (TTM) | Receivables turnover (TTM) | Revenues per employee (TTM) | Return on avg assets (TTM) | Return on avg assets (5 yr avg) | Return on investment (TTM) | Return on investment (5 yr avg) | Gross margin (TTM) | Gross margin (5 yr avg) | Net profit margin (TTM) | Net Profit margin (5 yr avg) | Quick ratio (MRQ) | Interest coverage (TTM) | Total debt to capital (MRQ) | Payout ratio (5 yr avg) | Revenue (YOY change %) | Revenue (5 yr growth rate) | Net income (YOY change %) | Net income (5 yr growth rate) | Capital expenditure (5 yr growth rate) | Dividend (5 yr growth rate) |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Newron Pharmaceuticals SpA | 6.47m | -17.48m | 141.13m | 23.00 | -- | -- | -- | 21.81 | -0.9605 | -0.9605 | 0.3555 | -1.50 | 0.247 | -- | 3.46 | 281,354.00 | -66.74 | -37.10 | -109.83 | -43.98 | 93.37 | 91.72 | -270.17 | -270.48 | -- | -3.53 | 2.71 | -- | 48.62 | 17.61 | 7.25 | -- | -22.76 | -- |
| Idorsia Ltd | 74.12m | -296.43m | 142.75m | 938.00 | -- | -- | -- | 1.93 | -1.68 | -1.68 | 0.3831 | -5.98 | 0.1271 | 0.236 | 56.93 | 79,021.32 | -50.85 | -46.72 | -123.79 | -53.84 | 77.71 | -- | -399.92 | -709.80 | 0.4153 | -21.55 | 206.68 | -- | 56.93 | 20.25 | 64.01 | -- | -8.01 | -- |
| Xlife Sciences AG | 990.28k | 21.24m | 165.94m | 17.00 | 12.13 | 0.6041 | 5.24 | 167.57 | 2.38 | 2.38 | 0.1215 | 47.84 | 0.002 | -- | 0.2013 | 58,251.77 | 3.17 | -- | 3.98 | -- | 54.46 | -- | 1,579.69 | -- | -- | -- | 0.1313 | -- | -3.85 | -- | 3.96 | -- | -- | -- |
| Molecular Partners AG | 7.86m | -57.63m | 194.35m | 162.00 | -- | 1.03 | -- | 24.72 | -1.75 | -1.75 | 0.2386 | 4.69 | 0.0392 | -- | 3.22 | 46,797.62 | -28.73 | -11.83 | -30.81 | -14.69 | -- | 99.28 | -732.97 | -45.30 | -- | -- | 0.0192 | -- | -96.29 | -7.43 | -152.59 | -- | -1.40 | -- |
| Basilea Pharmaceutica AG Allschwil | 149.02m | -652.00k | 534.03m | 156.00 | -- | 29.28 | 465.19 | 3.58 | -0.2814 | -0.2814 | 11.54 | 1.38 | 0.7118 | 1.22 | 4.40 | 1,013,755.00 | -0.3114 | -1.86 | -0.4156 | -2.99 | 76.57 | 83.45 | -0.4375 | -2.99 | 3.27 | -1.38 | 0.8508 | -- | 6.68 | 3.53 | -13.96 | -- | 11.17 | -- |
| Kuros Biosciences AG | 52.54m | -8.89m | 842.02m | 80.00 | -- | 13.69 | -- | 16.03 | -0.2295 | -0.2295 | 1.73 | 1.64 | 0.6755 | 1.95 | 7.89 | 656,775.00 | -11.42 | -13.47 | -13.53 | -14.84 | 79.13 | 78.73 | -16.91 | -81.48 | 2.17 | -- | 0.0847 | -- | 86.61 | 115.93 | 5.95 | -- | -13.21 | -- |
| BB BIOTECH AG | 270.66m | 125.36m | 1.99bn | -- | 15.84 | 0.8843 | -- | 7.36 | 2.27 | 2.27 | 4.95 | 40.66 | 0.1077 | -- | -- | -- | 4.99 | 2.34 | 5.64 | 2.52 | 97.86 | 99.06 | 46.32 | 35.40 | -- | 2.17 | 0.1096 | 217.78 | -57.97 | -37.98 | 42.26 | -- | -- | -8.09 |
Data as of Nov 22 2024. Currency figures normalised to Basilea Pharmaceutica AG Allschwil's reporting currency: Swiss Franc CHF
23.39%Per cent of shares held by top holders
| Holder | Shares | % Held |
|---|---|---|
| Black Creek Investment Management, Inc.as of 24 Oct 2024 | 647.22k | 4.91% |
| The Vanguard Group, Inc.as of 06 Nov 2024 | 431.52k | 3.28% |
| UBS Asset Management Switzerland AGas of 05 Nov 2024 | 426.40k | 3.24% |
| Braginsky Family Office AGas of 13 Sep 2023 | 391.68k | 2.97% |
| Z�rcher Kantonalbank (Investment Management)as of 30 Aug 2024 | 365.62k | 2.78% |
| ACATIS Investment Kapitalverwaltungsgesellschaft mbHas of 30 Sep 2024 | 332.68k | 2.53% |
| BlackRock Fund Advisorsas of 07 Nov 2024 | 173.28k | 1.32% |
| Norges Bank Investment Managementas of 30 Jun 2024 | 116.67k | 0.89% |
| Dimensional Fund Advisors LPas of 07 Nov 2024 | 107.77k | 0.82% |
| DWS Investments (UK) Ltd.as of 07 Nov 2024 | 86.98k | 0.66% |
More ▼
Data from 13 Sep 2023 - 31 Oct 2024Source: FactSet Research Systems Inc.
